These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27466218)

  • 1. Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.
    van Raalte DH; Bunck MC; Smits MM; Hoekstra T; Cornér A; Diamant M; Eliasson B; Marja-RiittaTaskinen ; Heine RJ; Smith U; HanneleYki-Järvinen ; Mari A
    Eur J Endocrinol; 2016 Oct; 175(4):345-52. PubMed ID: 27466218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
    Bunck MC; Cornér A; Eliasson B; Heine RJ; Shaginian RM; Taskinen MR; Smith U; Yki-Järvinen H; Diamant M
    Diabetes Care; 2011 Sep; 34(9):2041-7. PubMed ID: 21868779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
    Arnolds S; Dellweg S; Clair J; Dain MP; Nauck MA; Rave K; Kapitza C
    Diabetes Care; 2010 Jul; 33(7):1509-15. PubMed ID: 20357372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
    Gastaldelli A; Balas B; Ratner R; Rosenstock J; Charbonnel B; Bolli GB; Boldrin M; Balena R
    Diabetes Obes Metab; 2014 Feb; 16(2):170-8. PubMed ID: 23911196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E
    Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
    Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
    Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M; Bajaj M
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
    DeFronzo RA; Triplitt C; Qu Y; Lewis MS; Maggs D; Glass LC
    Diabetes Care; 2010 May; 33(5):951-7. PubMed ID: 20107105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
    Retnakaran R; Pu J; Ye C; Emery A; Kramer CK; Zinman B
    Cardiovasc Diabetol; 2023 Mar; 22(1):50. PubMed ID: 36894921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
    Kang C; Qiao Q; Tong Q; Bai Q; Huang C; Fan R; Wang H; Kaliannan K; Wang J; Xu J
    Sci Rep; 2021 Oct; 11(1):20062. PubMed ID: 34625598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.
    Retnakaran R; Ye C; Emery A; Kramer CK; Zinman B
    Nat Commun; 2022 Oct; 13(1):6109. PubMed ID: 36244997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
    Torimoto K; Okada Y; Mori H; Otsuka T; Kawaguchi M; Matsuda M; Kuno F; Sugai K; Sonoda S; Hajime M; Tanaka K; Arao T; Tanaka Y
    Cardiovasc Diabetol; 2015 Feb; 14():25. PubMed ID: 25849903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.